This live session provides a focused overview of novel psychoactive substances, emphasizing recognition, clinical management, and emerging trends in the illicit drug supply relevant to addiction medicine practice.
What This Includes
• Categories of novel psychoactive substances, including synthetic stimulants, cannabinoids, hallucinogens, and opioids• Patterns of use and evolving drug markets• Variability in substance composition, including adulterants and unregulated compounds• Challenges in detection and interpretation of toxicology results• Clinical presentations of intoxication, including sympathomimetic and serotonergic toxicity• Recognition and management of intoxication syndromes using supportive care strategies• Practical approaches to evaluating and managing patients exposed to novel psychoactive substances
What to Expect
• Live, faculty-led instruction delivered in an interactive online format• Discussion of emerging substances and evolving trends in the illicit drug supply• Structured content aligned with the ACAAM National Addiction Medicine Didactic Curriculum and ABPM content areas• Case-based examples highlighting clinical presentation and management strategies• Practical guidance for recognizing and responding to novel psychoactive substance exposures in clinical settings
Ashley Haynes, MD
Dr. Haynes is a Clinical Assistant Professor of Psychiatry and Behavioral Sciences at the University of Kansas School of Medicine. She serves as Program Director of the Addiction Medicine Fellowship and has clinical roles in addiction medicine and toxicology.
She received her medical degree from the University of Kansas School of Medicine and completed combined residency training in Emergency Medicine and Internal Medicine, followed by a fellowship in Medical Toxicology. Her work focuses on addiction medicine and the management of substance‑related toxicities.
To support a meaningful learning experience and recognize your participation: